+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.

Age: 42Days - 98DaysAll GendersPhase 3
78 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.

Age: 1Day - 49YearsAll GendersPhase 3
219 locations
E

Actively Recruiting

Researchers are evaluating whether a comprehensive nurse-led program called BEST CARE ICTUSHC can reduce complications and improve recovery for adults aged 18 and older hospitalized with acute ischemic or hemorrhagic stroke in hospitals lacking specialized Stroke Units. The study aims to see if this program improves early detection of swallowing difficulties to prevent pneumonia and reduces attention problems like hemineglect, enhancing quality of life up to six months after discharge. This trial compares patients receiving the BEST CARE ICTUSHC program with those receiving usual hospital care in a stepped-wedge design across multiple hospitals. The BEST CARE ICTUSHC intervention includes specialized training for nursing staff, systematic use of the Modified Swallowing Assessment to detect dysphagia, and the FLECHA Project, which adapts the patients environment with visual signs, spatial reorganization, and QR code-guided care plans tailored to stroke type and side. It also involves strict monitoring protocols for temperature, blood sugar, and blood pressure, plus early removal of invasive devices. During the control phase, usual care is provided without standardized dysphagia screening. The intervention phase adds educational outreach, compensatory care strategies, and ongoing support to ensure program implementation. Participants will be monitored from admission through hospitalization, discharge, and follow-up at 30 days and six months post-discharge. Assessments include swallowing tests, evaluation of hemineglect using the Catherine Bergego Scale, and health-related quality of life measurements. Vital signs and device use are tracked daily during hospital stay. Follow-up calls collect health and quality of life data. The study uses statistical methods to account for hospital differences and time effects, aiming to understand both clinical outcomes and how the program integrates into routine care.

Age: 18Years +All GendersPhase Not Applicable
4 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations